Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Neesgaard, B, Pelchen-Matthews, A, Ryom, L, Florence, E, Peters, L, Roen, A, Svedhem, V, Clarke, A, Benfield, T, Mitsura, V, Moreno, S, Beniowski, M, Begovac, J, Matulionyte, R, Trofimova, T, Elbirt, D, Kundro, M, Vullo, V, Behrens, G, Staub, T, Ragone, L, Vannappagari, V, Lundgren, J, Mocroft, A & EuroSIDA study 2019, 'Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe' AIDS (London, England), bind 33, nr. 13, s. 2013-2024. https://doi.org/10.1097/QAD.0000000000002320

APA

CBE

Neesgaard B, Pelchen-Matthews A, Ryom L, Florence E, Peters L, Roen A, Svedhem V, Clarke A, Benfield T, Mitsura V, Moreno S, Beniowski M, Begovac J, Matulionyte R, Trofimova T, Elbirt D, Kundro M, Vullo V, Behrens G, Staub T, Ragone L, Vannappagari V, Lundgren J, Mocroft A, EuroSIDA study. 2019. Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe. AIDS (London, England). 33(13):2013-2024. https://doi.org/10.1097/QAD.0000000000002320

MLA

Vancouver

Author

Neesgaard, Bastian ; Pelchen-Matthews, Annegret ; Ryom, Lene ; Florence, Eric ; Peters, Lars ; Roen, Ashley ; Svedhem, Veronika ; Clarke, Amanda ; Benfield, Thomas ; Mitsura, Viktar ; Moreno, Santiago ; Beniowski, Marek ; Begovac, Josip ; Matulionyte, Raimonda ; Trofimova, Tatyana ; Elbirt, Daniel ; Kundro, Mariana ; Vullo, Vincenzo ; Behrens, Georg ; Staub, Therese ; Ragone, Leigh ; Vannappagari, Vani ; Lundgren, Jens ; Mocroft, Amanda ; EuroSIDA study. / Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe. I: AIDS (London, England). 2019 ; Bind 33, Nr. 13. s. 2013-2024.

Bibtex

@article{cbbb853694b841a69a4308f7d4d0f3f1,
title = "Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe",
abstract = "OBJECTIVE: To assess the use of two-drug antiretroviral regimens (2DR) and virologic and immunologic outcomes compared with three-drug regimens (3DR) in the EuroSIDA cohort.DESIGN: Multicentre, prospective cohort study.METHODS: Logistic regression was used to analyse the uptake and outcomes among HIV-positive individuals who started or switched to a 2DR compared with those on a 3DR. Virologic outcomes were assessed on-treatment as the proportion of individuals with controlled viral load (<400 copies/ml), or with a composite modified FDA snapshot endpoint (mFDA), with mFDA success defined as controlled viral load at 6 months or 12 months for individuals with a known viral load, no regimen changes, AIDS or death. Immunologic response was defined as a 100 cells/μl or a 25{\%} increase in CD4 cell counts from baseline.RESULTS: Between 1 July 2010 and 31 December 2016, 423 individuals started or switched to a 2DR (eight antiretroviral-naive) and 4347 started a 3DR (566 naive). Individuals on 2DR tended to have suppressed viral load, higher CD4 cell counts and more comorbidities at baseline compared with those on 3DR. There were no differences in the proportions of individuals who obtained on-treatment or mFDA success, and no significant differences in the adjusted odds ratios for mFDA success or immunologic responses between the 2DR and 3DR groups at 6 months or 12 months.CONCLUSION: In routine clinical practice, 2DR were largely used for virologically suppressed individuals with higher cumulative exposure to antiretrovirals and comorbidities. Virologic and immunologic outcomes were similar among those on 2DR or 3DR, although confounding by indication cannot be fully excluded due to the observational nature of the study.",
keywords = "combination antiretroviral treatment, dual therapy, HIV, nucleot(s)ide reverse transcriptase inhibitor-sparing regimens, simplification, two-drug regimens",
author = "Bastian Neesgaard and Annegret Pelchen-Matthews and Lene Ryom and Eric Florence and Lars Peters and Ashley Roen and Veronika Svedhem and Amanda Clarke and Thomas Benfield and Viktar Mitsura and Santiago Moreno and Marek Beniowski and Josip Begovac and Raimonda Matulionyte and Tatyana Trofimova and Daniel Elbirt and Mariana Kundro and Vincenzo Vullo and Georg Behrens and Therese Staub and Leigh Ragone and Vani Vannappagari and Jens Lundgren and Amanda Mocroft and {EuroSIDA study}",
year = "2019",
month = "11",
day = "1",
doi = "10.1097/QAD.0000000000002320",
language = "English",
volume = "33",
pages = "2013--2024",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams & Wilkins",
number = "13",

}

RIS

TY - JOUR

T1 - Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe

AU - Neesgaard, Bastian

AU - Pelchen-Matthews, Annegret

AU - Ryom, Lene

AU - Florence, Eric

AU - Peters, Lars

AU - Roen, Ashley

AU - Svedhem, Veronika

AU - Clarke, Amanda

AU - Benfield, Thomas

AU - Mitsura, Viktar

AU - Moreno, Santiago

AU - Beniowski, Marek

AU - Begovac, Josip

AU - Matulionyte, Raimonda

AU - Trofimova, Tatyana

AU - Elbirt, Daniel

AU - Kundro, Mariana

AU - Vullo, Vincenzo

AU - Behrens, Georg

AU - Staub, Therese

AU - Ragone, Leigh

AU - Vannappagari, Vani

AU - Lundgren, Jens

AU - Mocroft, Amanda

AU - EuroSIDA study

PY - 2019/11/1

Y1 - 2019/11/1

N2 - OBJECTIVE: To assess the use of two-drug antiretroviral regimens (2DR) and virologic and immunologic outcomes compared with three-drug regimens (3DR) in the EuroSIDA cohort.DESIGN: Multicentre, prospective cohort study.METHODS: Logistic regression was used to analyse the uptake and outcomes among HIV-positive individuals who started or switched to a 2DR compared with those on a 3DR. Virologic outcomes were assessed on-treatment as the proportion of individuals with controlled viral load (<400 copies/ml), or with a composite modified FDA snapshot endpoint (mFDA), with mFDA success defined as controlled viral load at 6 months or 12 months for individuals with a known viral load, no regimen changes, AIDS or death. Immunologic response was defined as a 100 cells/μl or a 25% increase in CD4 cell counts from baseline.RESULTS: Between 1 July 2010 and 31 December 2016, 423 individuals started or switched to a 2DR (eight antiretroviral-naive) and 4347 started a 3DR (566 naive). Individuals on 2DR tended to have suppressed viral load, higher CD4 cell counts and more comorbidities at baseline compared with those on 3DR. There were no differences in the proportions of individuals who obtained on-treatment or mFDA success, and no significant differences in the adjusted odds ratios for mFDA success or immunologic responses between the 2DR and 3DR groups at 6 months or 12 months.CONCLUSION: In routine clinical practice, 2DR were largely used for virologically suppressed individuals with higher cumulative exposure to antiretrovirals and comorbidities. Virologic and immunologic outcomes were similar among those on 2DR or 3DR, although confounding by indication cannot be fully excluded due to the observational nature of the study.

AB - OBJECTIVE: To assess the use of two-drug antiretroviral regimens (2DR) and virologic and immunologic outcomes compared with three-drug regimens (3DR) in the EuroSIDA cohort.DESIGN: Multicentre, prospective cohort study.METHODS: Logistic regression was used to analyse the uptake and outcomes among HIV-positive individuals who started or switched to a 2DR compared with those on a 3DR. Virologic outcomes were assessed on-treatment as the proportion of individuals with controlled viral load (<400 copies/ml), or with a composite modified FDA snapshot endpoint (mFDA), with mFDA success defined as controlled viral load at 6 months or 12 months for individuals with a known viral load, no regimen changes, AIDS or death. Immunologic response was defined as a 100 cells/μl or a 25% increase in CD4 cell counts from baseline.RESULTS: Between 1 July 2010 and 31 December 2016, 423 individuals started or switched to a 2DR (eight antiretroviral-naive) and 4347 started a 3DR (566 naive). Individuals on 2DR tended to have suppressed viral load, higher CD4 cell counts and more comorbidities at baseline compared with those on 3DR. There were no differences in the proportions of individuals who obtained on-treatment or mFDA success, and no significant differences in the adjusted odds ratios for mFDA success or immunologic responses between the 2DR and 3DR groups at 6 months or 12 months.CONCLUSION: In routine clinical practice, 2DR were largely used for virologically suppressed individuals with higher cumulative exposure to antiretrovirals and comorbidities. Virologic and immunologic outcomes were similar among those on 2DR or 3DR, although confounding by indication cannot be fully excluded due to the observational nature of the study.

KW - combination antiretroviral treatment

KW - dual therapy

KW - HIV

KW - nucleot(s)ide reverse transcriptase inhibitor-sparing regimens

KW - simplification

KW - two-drug regimens

UR - http://www.scopus.com/inward/record.url?scp=85072903353&partnerID=8YFLogxK

U2 - 10.1097/QAD.0000000000002320

DO - 10.1097/QAD.0000000000002320

M3 - Journal article

VL - 33

SP - 2013

EP - 2024

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 13

ER -

ID: 57712284